A phase II trial of imatinib in patients with refractory/relapsed myeloma

Angela Dispenzieri, Morie A. Gertz, Martha Q. Lacy, Susan M. Geyer, Phillip R. Greipp, S. Vincent Rajkumar, Teresa Kimlinger, John A. Lust, Rafael Fonseca, Jacob Allred, Thomas E. Witzig

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Although imatinib was designed to specifically inhibit the bcr-abl gene product, it inhibits other receptor tyrosine kinases including c-kit. As pre-clinical data, 126 patients with plasma cell disorders and 19 controls were evaluated for c-kit expression. Patients were eligible for the treatment trial if they had relapsed/refractory myeloma. The primary end-point of the study was response. Of the 145 studied before the trial, c-kit expression was present on the bone marrow plasma cells of control (11%), AL amyloid (53%), MGUS (47%), SMM (67%) and MM (42%) patients. Twenty-three MM patients were enrolled on the therapeutic trial (imatinib 400 mg daily) and 52% had positive c-kit staining. There were no responses. The median duration of treatment was 48 days (range: 12-349). Patients ended treatment due to progressive disease (18 patients), death (3) and other (2). The data suggest that imantinib is not an active agent in patients with relapsed or refractory multiple myeloma.

Original languageEnglish (US)
Pages (from-to)39-42
Number of pages4
JournalLeukemia and Lymphoma
Issue number1
StatePublished - Jan 2006


  • Amyloid
  • Myeloma
  • Therapy
  • c-kit

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'A phase II trial of imatinib in patients with refractory/relapsed myeloma'. Together they form a unique fingerprint.

Cite this